Denali Therapeutics Inc. (DNLI) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है South San Francisco, CA, United States. वर्तमान CEO हैं Ryan J. Watts.
DNLI के पास है IPO तिथि 2017-12-08, 443 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $3.44B.
Denali Therapeutics Inc. is a biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing therapeutic candidates for neurodegenerative diseases. The company's pipeline includes several clinical-stage programs, such as BIIB122/DNL151, a LRRK2 inhibitor in Phase I/Ib trials for Parkinson's disease, DNL310 for Hunter syndrome, DNL343 for ALS, and SAR443122/DNL758 for cutaneous lupus erythematosus. Denali has established strategic collaborations with leading pharmaceutical and research institutions including Takeda, Genentech, Sanofi, and Harvard University to advance its antisense therapy platform and other neurodegenerative disease treatments. The company was incorporated in 2013 and operates under its current name since March 2015.
